New combo shows promise for elderly lymphoma patients
NCT ID NCT04765111
First seen Nov 10, 2025 · Last updated Apr 24, 2026 · Updated 23 times
Summary
This study tests a combination of two drugs, acalabrutinib and rituximab, in people aged 65 and older with newly diagnosed mantle cell lymphoma. The goal is to see if the combo can control the cancer while causing fewer severe side effects. About 53 participants will receive the treatment, and researchers will track how many achieve complete remission and any serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.